Pharmacy & Therapeutics - December 2008 - (Page 682)

CONTENTS Cover: Fat cells. Colored scanning electron micrograph of four joined fat-storing cells (adipocytes). Each cell is 100 to 120 microns in diameter. Magnification, x 330. See continuing education article on page 724. (Credit: Steve Gschmeissner / Photo Researchers, Inc.) December 2008 FEATURES Interpreting Estimates of Treatment Effects Health care professionals must consider drug-related adverse events along with efficacy when they prescribe medications. In explaining such concepts as statistical significance and magnitude of effect, the author suggests how indirect comparisons of studies can be used to help guide treatment decisions, especially if patients are taking other agents and combination therapy. Stephen V. Faraone, PhD MEETING HIGHLIGHTS 700 DEPARTMENTS Editorial 685 David Nash, MD, MBA, discusses Pharmaceutical Industry Profile 2008, which documents the growth in spending and in product development by drug companies during the past two years. Medication Errors 686 Matthew Grissinger, RPh, FASCP, explains how hospital workers can prevent tragic outcomes by carefully labeling all medication containers and solutions. Prescription: Washington 687 Stephen Barlas discusses new rules that might allow consumers to sue pharmaceutical companies in state courts over drug labeling. New Drugs/Drug News/ New Medical Devices 688 From Banzel to Vimpat, P&T presents the latest FDA approvals, new indications, recalls, and industry updates. Drug Forecast 690 Authors Yero and Rey review tetrabenazine (Xenazine) for Huntington’s chorea. Chemotherapy Foundation Symposium XXVI: Innovative Cancer Therapy for Tomorrow Presentations included voreloxin for acute myelogenous leukemia; azacytidine (Vidaza) and decitabine (Depo-Cyt) for myelodysplastic syndromes; lenalidomide (Revlimid) for lymphoma; and dasatinib (Sprycel), nilotinib (Tasigna), and other investigational agents for chronic myelogenous leukemia. Marvin M. Goldenberg, PhD, RPh, MS 712 Fourth Annual Ophthalmic Drug Development and Delivery Summit Third Annual Onmark National Payor/Provider Forum Topics discussed at the ophthalmic meeting included medications for dry eye and for diabetes-related conditions. The Onmark Forum focused on the anticipated need for collaboration between oncologists and adjunctive personnel because of a workforce gap; online information gathering; and standardizing procedures. Walter Alexander CONTINUING EDUCATION CREDIT 721 Classification and Pharmacological Management Of Obesity Obesity can have deleterious effects on health, often leading to diabetes and cardiovascular disease. Bariatric surgery, diet and behavior modification, and current and investigational drug therapies are some of the tools that are available now to help the overweight patient population. Sarah R. Erlanger, PharmD, and Emily A. Henson, PharmD 724 CE Test and Forms 729 Season’s Greetings: Thanks to Our Readers and Reviewers 733 682 P&T® • December 2008 • Vol. 33 No. 12

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - December 2008

Pharmacy & Therapeutics - December 2008 Contents Editorial Medication Errors Prescription: Washington New Drugs/Drug News/ New Medical Devices Drug Forecast Interpreting Estimates of Treatment Effects Chemotherapy Foundation Symposium XXVI: Innovative Cancer Therapy for Tomorrow Third Annual Onmark National Payor/Provider Forum Fourth Annual Ophthalmic Drug Development and Delivery Summit Classification and Pharmacological Management Of Obesity CE Test and Forms Season’s Greetings: Thanks to Our Readers and Reviewers

Pharmacy & Therapeutics - December 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.